Pharmacokinetics of methylphenidate in man, rat and monkey
- PMID: 6410043
Pharmacokinetics of methylphenidate in man, rat and monkey
Abstract
The pharmacokinetics and bioavailability of methylphenidate (MPH) and a metabolite, ritalinic acid (RA), were studied in normal adults, children with hyperactivity, monkeys and rats. Adult males received 0.15 or 0.3 mg/kg of MPH orally and MPH and RA were analyzed in plasma samples obtained at various times after treatment. Maximal MPH concentrations in plasma were found to occur 2.2 hr after administration of either dose (range: 1.0-4.0). The mean (+/-S.E.) maximal concentration in plasma for MPH was 3.5 +/- 0.4 ng/ml after 0.15 mg/kg and 7.8 +/- 0.8 ng/ml after 0.3 mg/kg. MPH clearances were high (10.1 liters/hr/kg) and variable (range: 3.6-23.2) for the 0.3 mg/kg dose. Pharmacokinetic parameters for children receiving 0.3 mg/kg were essentially the same as for adults. RA plasma levels were 50 to 100 times greater than MPH levels in normal adults. The clearance of RA is less than that of MPH. The absolute bioavailability of MPH was found to be 0.19 in the rat and 0.22 in the monkey, suggesting substantial presystemic elimination of MPH.
Similar articles
-
Pharmacokinetics of methylphenidate in oral fluid and sweat of a pediatric subject.Forensic Sci Int. 2010 Mar 20;196(1-3):59-63. doi: 10.1016/j.forsciint.2009.12.038. Epub 2010 Jan 21. Forensic Sci Int. 2010. PMID: 20096514
-
A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects.J Clin Pharmacol. 2004 Feb;44(2):173-8. doi: 10.1177/0091270003261899. J Clin Pharmacol. 2004. PMID: 14747426 Clinical Trial.
-
Comparative pharmacokinetics and tissue distribution of the d-enantiomers of para-substituted methylphenidate analogs.Drug Metab Dispos. 1999 Jun;27(6):645-50. Drug Metab Dispos. 1999. PMID: 10348792
-
Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?J Clin Psychopharmacol. 2008 Jun;28(3 Suppl 2):S54-61. doi: 10.1097/JCP.0b013e3181733560. J Clin Psychopharmacol. 2008. PMID: 18480678 Review.
-
OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.Expert Rev Neurother. 2009 Aug;9(8):1121-31. doi: 10.1586/ern.09.65. Expert Rev Neurother. 2009. PMID: 19673602 Review.
Cited by
-
Methylphenidate and memory: dissociated effects in hyperactive children.Psychopharmacology (Berl). 1986;90(2):211-6. doi: 10.1007/BF00181244. Psychopharmacology (Berl). 1986. PMID: 3097701 Clinical Trial.
-
Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage.Eur J Drug Metab Pharmacokinet. 2017 Apr;42(2):295-307. doi: 10.1007/s13318-016-0346-1. Eur J Drug Metab Pharmacokinet. 2017. PMID: 27220743 Free PMC article.
-
Dose-response characteristics of methylphenidate on locomotor behavior and on sensory evoked potentials recorded from the VTA, NAc, and PFC in freely behaving rats.Behav Brain Funct. 2006 Jan 17;2:3. doi: 10.1186/1744-9081-2-3. Behav Brain Funct. 2006. PMID: 16417623 Free PMC article.
-
A review of psychostimulant-induced neuroadaptation in developing animals.Neurosci Bull. 2011 Jun;27(3):197-214. doi: 10.1007/s12264-011-1004-x. Neurosci Bull. 2011. PMID: 21614102 Free PMC article. Review.
-
Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers.Eur J Clin Pharmacol. 1993;44(1):79-84. doi: 10.1007/BF00315285. Eur J Clin Pharmacol. 1993. PMID: 8436161
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources